Navigation Links
CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006

disease progressing well * Several potential lead candidates have already been identified

Business development

* M6G partnering process has commenced. Phase III clinical data clarifies the value of the opportunity * Licensing discussions ongoing in relation to earlier portfolio programmes * Agreement signed with Rodman & Renshaw - appointed to assist in partnering of M6G

Corporate

* Scientific Advisory Board (SAB) strengthened * Further progress in portfolio of carried interests

Financial

* Fund raising of ?.5 million net of expenses through placing new shares * Increased net loss after tax of ?.7 million (2005: ?.7million restated) due to planned increase in clinical development activities on M6G Phase III trial * Cash at year end of ?.3 million (2005: ?.5 million)

Alan Goodman, Chairman of CeNeS, said:

"CeNeS has taken a major step forward in the development of M6G and is now well placed to successfully commercialise its lead asset. The partnering process has begun and the Company is well positioned to deliver significant value to shareholders in the near-term."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com.

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomi
'"/>




Page: 1 2 3

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:11/25/2008)...spondents against expanding statin use broadly in ...S, N.J., Nov. 25 JUPITER, a clinic...diovascular risk of healthy patients with elevated...der adults, according to a national poll directed ...ook part in the online poll conducted by medical n...
(Date:11/25/2008).... 25 Pharmacyclics, Inc....ny has completed a Phase 1,clinical trial with PC...l-molecule Factor VIIa inhibitor. The trial was co...luate the safety and pharmacologic effect of,PCI-...ed in a linear dose,response in the International...
(Date:11/24/2008)...SAKA, Japan, Nov. 24 Takeda Pharma...idiary, Takeda Global Research & Development C...tis Advisory Committee of the U.S. Food and Drug A...ve febuxostat for the treatment of hyperuricemia ...favor of approval, with one panel member abstainin...
(Date:11/24/2008)... Cancer Awareness Month , , Oak Brook, Ill.... Society for Gastrointestinal Endoscopy (ASGE) and...up this November to raise awareness about pancreat...d the resources that are available for them. , ...e of cancer deaths in the U.S. In 2008, an estimat...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 1New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 2New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 3New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 4History Making Obesity Awareness Event Scheduled to Take Place in Washington DC on June 17 2008 19035 1History Making Obesity Awareness Event Scheduled to Take Place in Washington DC on June 17 2008 19035 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 1Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 4Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 5Ancient protein offers clues to killer condition 3266 1Ancient protein offers clues to killer condition 3266 2
...720 Mechanisms in Multiple,Sclerosis May Include D... studies suggest FTY720 stimulates cells,that may ...f the,CNS affected by multiple sclerosis , ·...,sclerosis Phase II clinical study found that the ...s significantly lower in the,FTY720 groups compare...
...)--May 4, 2007 - New data from a,randomized, doubl...E(R) (glatiramer acetate injection) along with the... (Gd)-enhancing lesions,of the brain by 63 percent...ing multiple sclerosis (RRMS), as measured by,magn...ceiving,COPAXONE(R) alone. Additionally, the nine-...
Other Medicine Technology:Data to be presented at AAN Meeting -Study results of drug,candidate for MS 2Data to be presented at AAN Meeting -Study results of drug,candidate for MS 3Data to be presented at AAN Meeting -Study results of drug,candidate for MS 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 5Data to be presented at AAN Meeting -Study results of drug,candidate for MS 6Data to be presented at AAN Meeting -Study results of drug,candidate for MS 7Data to be presented at AAN Meeting -Study results of drug,candidate for MS 8Data to be presented at AAN Meeting -Study results of drug,candidate for MS 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:12/2/2008)...g Improves Service and Efficiency by Automating Ac...NGHAM, Mass., Dec. 2 Courion(R) C...liance, today announced that Brookdale Senior Livi...ior living communities, has deployed Courion,s Ent...ecure access to enterprise applications and other ...
(Date:12/2/2008)...rate With Traditional Holiday Cuisine , , M...inistries ( www.angelfoodministries.com ), an orga...at low-costs, to anyone who wishes to participate,... a specialty Christmas Box which includes everythi...ost sites are now taking orders throughout the cou...
(Date:12/2/2008)...and Professionals Shares Experience , Dealing w...ation, More , , WASHINGTON, Dec. 2 /PRNewsw...nal disability association working on equity, dive...cant disabilities announces the official launch of...ry accessible to people with disabilities, family ...
(Date:12/2/2008)...available to seniors , , DETROIT, Dec. 2 /P...P) is adding acupuncture and chiropractic services...re Advantage members beginning January 1, 2009. HA...ncourages Medicare beneficiaries to choose activit...ck in their wallets. , , HAP offers a Flex...
Breaking Medicine News(10 mins):Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 2Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 3Health News:Angel Food Ministries to Distribute Holiday Grocery Relief 2Health News:New Website Links People With Disabilities to Peers for Help 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 3
...analyzing the neuronal receptor activity in the po...enia, researchers at the University of Pennsylvani...ntists at the City University of New York, have fo...igh level of erbB4 receptor activity and reduced N...
...ding to the infectious disease expert the afro Ame...an papillomavirus (HPV). This vaccine was recently...ced in the Lancet Infectious Disease by researcher...al School. They said that the best ay for distri...
...al evidence of Huntington disease curing medicine ...f British Columbia's Centre for Molecular // Medic...h mouse. This provided hope in curing the disease ...urnal, Dr. Michael Hayden and colleagues discovere...
...elaide, Frozen pasta (such as frozen Beef Ravioli ...oisoning in six people //. The classical symptoms...iarrhoea.South Australian Health Department public...due to non-removal of the shell and eating the pro...
Other Medicine News:Health News:Schizophrenia Complicates With Altered Receptor Activity 2Health News:Schizophrenia Complicates With Altered Receptor Activity 3Health News:Afro American Women at a High Risk of HPV and Hence Should Be Vaccinated 2Health News:Animal Study Found Cure For Huntington Disease 2
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: